CLOs on the Move

SurgePays, Inc. (NASDAQ: SURG)

www.surgepays.com

 
The Company SurgePays brings financial and telecom products to the underbanked and underserved populations of the United States where they live and where they shop. Goal in Process Building the largest direct distribution network of underbanked products and services in the country. The Market The underbanked do the majority of their financial transactions at their trusted local convenience store thats closest to their home. SurgePays utilizes these stores as the points of distribution into these communities. As we onboard stores to our fintech software platform, we enable the clerk at that store to perform transactions such as prepaid wireless activation ...
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

EORM.

EORM, Inc.. is a San Jose, CA-based company in the Business Services sector.

MCS Personnel

MCS Personnel Incorporated is a Houston, TX-based company in the Business Services sector.

EPL Bio-analytical Services

EPL Bio-analytical Services is a Harristown, IL-based company in the Business Services sector.

TWISTED PAIR GROUP

TWISTED PAIR GROUP is a New York, NY-based company in the Business Services sector.

enGene

At enGene, we are at the vanguard of a new era in genetic medicine: Our novel Dually Derivatized Oligochitosan® (DDX) gene delivery platform is designed to enable localized delivery of multiple gene cargos, including RNA and DNA, directly to mucosal tissues and other organs — potentially overcoming the limitations of viral-based gene therapies and advancing gene therapy beyond rare genetic diseases into the mainstream of clinical practice. Our breakthrough Dually Derivatized Oligochitosan® (DDX) platform opens possibilities for streamlining the use of genetic medicines in the treatment of serious diseases, especially diseases afflicting mucosal tissues. Our lead product candidate, EG-70 (detalimogene voraplasmid), is a non-viral immunotherapy in development to treat non-muscle invasive bladder cancer (NMIBC), a disease with a significant patient burden, high clinical needs, and massive healthcare system economic impact. Based on its preliminary efficacy and safety profile and ease of administration by urologists, EG-70, which is currently in a pivotal trial, can potentially benefit patients across a wide variety of clinical settings. As enGeneers, we are boldly focused on patients needs. We are a team of passionate experts with extensive experience in drug development and commercialization across oncology, respiratory, and several other therapeutic areas. Nasdaq: ENGN